Pharmacokinetic drug evaluation of ribociclib for the treatment of metastatic, hormone-positive breast cancer

References

• Sherr CJ, Beach D, Shapiro GI. Targeting CDK4 and CDK6: from discovery to therapy. Cancer Discov. 2015;6:353–367.
   PubMed Web of Science ®Google Scholar
• Shapiro GI. Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol. 2006;24:1770–1783.
   PubMed Web of Science ®Google Scholar
• Ortega S, Malumbres M, Barbacid M. Cyclin D-dependent kinases, INK4 inhibitors and cancer. Biochim Biophys Acta. 2002;1602:73–87.
   PubMed Web of Science ®Google Scholar
• Baker SJ, Reddy EP. CDK4: a key player in the cell cycle, development, and cancer. Genes Cancer. 2012;3:658–669.
   PubMedGoogle Scholar
• Zhang YX, Sicinska E, Czaplinski JT, et al. Antiproliferative effects of CDK4/6 inhibition in CDK4-amplified human liposarcoma in vitro and in vivo. Mol Cancer Ther. 2014;13:2184–2193.
   PubMed Web of Science ®Google Scholar
• Liggett WH Jr, Sidransky D. Role of the p16 tumor suppressor gene in cancer. J Clin Oncol. 1998;16:1197–1206.
   PubMed Web of Science ®Google Scholar
• Kim S, Loo A, Chopra R, et al. Abstract PR02: LEE011: An orally bioavailable, selective small molecule inhibitor of CDK4/6– Reactivating Rb in cancer. Mol Cancer Ther. 2013;12(11 Suppl):PR02.
   Google Scholar
• Rader J, Russell MR, Hart LS, et al. Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma. Clin Cancer Res. 2013;19:6173–6182.
   PubMed Web of Science ®Google Scholar
• O’Brien N, Di Tomaso E, Ayala R, et al. In vivo efficacy of combined targeting of CDK4/6, ER and PI3K signaling in ERþ breast cancer [abstract]. Cancer Res 74: Abstract nr 4756.
   Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2012 Jan;67(1):7–30.
   Web of Science ®Google Scholar
• The Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490:61–70.
   PubMed Web of Science ®Google Scholar
• Coates AS, Winer EP, Goldhirsch A, et al. Tailoring therapies-improving the management of early breast cancer: St Gallen International Expert Consensus on the primary therapy of early breast cancer 2015. Ann Oncol. 2015;26:1533–1546.
   PubMed Web of Science ®Google Scholar
• Senkus E, Kyriakides E, Ohno S, et al. Primary breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(Supplement 5):v8–v30.
   PubMed Web of Science ®Google Scholar
• Shapiro G, Rosen LS, Tolcher AW, et al. A first-in-human phase I study of the CDK4/6 inhibitor, LY2835219, for patients with advanced cancer [abstract]. J Clin Oncol. 2013;31(Suppl.):a2500.
   PubMed Web of Science ®Google Scholar
• Goldman JW, Gandhi L, Patnaiket A, et al. Clinical activity of LY2835219, a novel cell cycle inhibitor selective for CDK4 and CDK6, in patients with non-small cell lung cancer [abstract]. J Clin Oncol. 2014;32(Suppl.):8026.
   Google Scholar
• Patnaik A, Rosen LS, Tolaney SM, et al. Clinical activity of LY2835219, a novel cell cycle inhibitor selective for CDK4 and CDK6, in patients with metastatic breast cancer [abstract]. Cancer Res. 2014;74:CT232.
   Web of Science ®Google Scholar
• Flaherty KT, Lorusso PM, Demichele A, et al. Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer. Clin Cancer Res. 2012;18(2):568–576.
   Google Scholar
• Schwartz GK, LoRusso PM, Dickson MA, et al. Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (schedule 2/1). Br J Cancer. 2011;104:1862–1868.
   PubMed Web of Science ®Google Scholar
• Leonard JP, Williams ME,, Goy A,, et al. Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma. Blood. 2012;119:4597–4607.
   PubMed Web of Science ®Google Scholar
• DeMichele A, Clark AS, Tan KS, et al. CDK 4/6 inhibitor palbociclib (PD0332991) in Rb+ advanced breast cancer: phase II activity, safety, and predictive biomarker assessment. Clin Cancer Res. 2015;21:995–1001.
   PubMed Web of Science ®Google Scholar
• Infante JR, Cassier PA, Gerecitano JF, et al. A phase I study of the single-agent CDK4/6 inhibitor LEE011 in pts with advanced solid tumors and lymphomas [abstract]. J Clin Oncol. 2014;32(Suppl.):2528.
   Google Scholar
• Sosman JA, Kittaneh M, Martijn P, et al. A phase 1b/2 study of LEE011 in combination with binimetinib (MEK162) in patients with NRAS-mutant melanoma: early encouraging clinical activity [abstract]. J Clin Oncol. 2014;32(Suppl.):9009.
   Google Scholar
• Munster PN, Paige Hamilton E, Franklin C, et al. Phase lb study of LEE011 and BYL719 in combination with letrozole in estrogen receptor-positive, HER2-negative breast cancer (ER+, HER2− BC) [abstract]. J Clin Oncol. 2014;32(Suppl.):533.
   Google Scholar
• Juric D, Hamilton E, Garcia Estevez L, et al. Abstract P5-19-24: phase Ib/II study of LEE011 and BYL719 and letrozole in ER+, HER2− breast cancer: safety, preliminary efficacy and molecular analysis. Cancer Res. 2015;75:P5-19-24.
   Web of Science ®Google Scholar
• Turner NC, Ro J,MD, André F, et al. Palbociclib in hormone-receptor-positive advanced breast cancer. N Engl J Med. 2015;373:209–219.
   PubMed Web of Science ®Google Scholar
• Finn RS, Martin M, Rugo H, et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med. 2016;375:1925–1936.
   PubMed Web of Science ®Google Scholar
• Cristofanilli M, Turner NC, Bondarenko I, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol. 2016 Apr;17(4):425–439.
   PubMed Web of Science ®Google Scholar
• Hortobagyi GN, Stemmer SM, Burris HA, et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med. 2016 Nov 3;375(18):1738–1748.
   PubMed Web of Science ®Google Scholar
• Infante JR, Cassier PA, Gerecitano JF, et al. A phase I study of the cyclin-dependent kinase 4/6 inhibitor ribociclib (lee011) in patients with advanced solid tumors and lymphomas. Clin Cancer Res. 2016 Dec 1;22(23):5696–5705.
   Web of Science ®Google Scholar
• Curigliano G, Gómez Pardo P, Meric-Bernstam F, et al. Ribociclib plus letrozole in early breast cancer: a presurgical, window-of-opportunity study. Breast. 2016 Aug;28:191–198.
   PubMed Web of Science ®Google Scholar